Drugs / MNV-BM-PLC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04548843 | Mar 2022 → Dec 2024 | mitochondrial disease | Minovia Therapeutics Ltd. | Withdrawn | No outcome recorded Stop: Enrollment |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MNV-BM-PLC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04548843 ↗ |
| Action | Restore | “This therapeutic process of mitochondrial augmentation provides the patient with healthy mitochondria carrying non-mutated/deleted mtDNA that can supplement mitochondrial...” NCT04548843 ↗ |
| Modality | Cell therapy | “MNV-BM-PLC is a personalized cell therapy based on autologous patient-derived Hematopoietic stem/progenitor cells (HSPCs) enriched with mitochondria isolated from healthy...” NCT04548843 ↗ |
| Route | Intravenous | “The MNV-BM-PLC (autologous CD34+ cells enriched with placenta-derived allogeneic mitochondria) infusion will be performed by standard IV procedure.” NCT04548843 ↗ |